United States

Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

8:01am EST
Change (% chg)

€-0.02 (-0.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Stentys 2016 annual revenues up 20 pct at 7.3 million euros
Thursday, 12 Jan 2017 11:45am EST 

Stentys SA : 2016 annual revenues up 20 pct at 7.3 million euros ($7.78 million) . Over Q4 2016, Stentys recorded revenues of almost 2.0 million euros, an increase of +5 pct compared with Q4 2015 . At December 31, 2016, Stentys had a cash position of 17 million euros versus 10.7 million euros at December 31, 2015 .In 2017, our ambition will be to accelerate our growth - CEO.  Full Article

Stentys Q3 revenue rises to 1.7 million euros
Wednesday, 12 Oct 2016 12:35pm EDT 

Stentys SA : Q3 revenue 1.7 million euros ($1.90 million) versus 1.6 million year ago .At Sept. 30, 2016, Stentys had cash and equivalents totaling 15.7 million euros compared with 18.1 million euros at june 30, 2016..  Full Article

Stentys reports 41 pct increase in revenues in Q2 2016
Tuesday, 12 Jul 2016 11:45am EDT 

Stentys SA : 41 pct increase in revenues in the second quarter of 2016 . Q2 revenue 2.1 million euros versus 1.5 million euros year ago .At June 30, 2016, Stentys had a cash position of 18.3 million euros.  Full Article

Stentys appoints Christophe Lottin as new CEO
Monday, 4 Jul 2016 12:12pm EDT 

Stentys SA : Appointment of cardiolovascular device veteran as new CEO . Christophe Lottin, ex second in command at stent company Hexacath, brings 20 years of sales and management experience .Gonzague Issenmann has organized his succession and will ensure a smooth transition over next quarter.  Full Article

Stentys SA' self-apposing coronary stent receives CE marking
Monday, 21 Mar 2016 02:00am EDT 

Stentys SA:Stentys announces the CE marking of the self-apposing Stent for left main coronary artery disease.  Full Article

Stentys successfully completes capital increase
Friday, 4 Mar 2016 12:59pm EST 

Stentys SA:Stentys successfully completes 12.6 million euro capital increase.Final gross proceeds of transaction amount to 12,648,919.50 euros.This is corresponding to issuance of 5,621,742 new shares.Total demand for this capital increase amounted to approximately 9.1 million euros, (subscription rate of approximately of 72.23 pct).  Full Article

Stentys says two applications at Leipzig University hospital
Thursday, 28 Jan 2016 12:00pm EST 

Stentys SA:Two successful interventions at the Leipzig University hospital.First use of self-apposing active stent for the lower limbs broadcast at international congress Leipzig interventional course‍​.  Full Article

Stentys ends recruitment for clinical study comparing Mistent to Xience
Wednesday, 9 Dec 2015 11:45am EST 

Stentys SA:Ends recruitment for clinical study comparing Mistent to Xience.Dessolve III clinical trial enrolled 1,400 "all-comers" patients.Results expected in H1 2017.  Full Article

Stentys confirms long-term performance of the sirolimus-eluting Self-Apposing stent
Monday, 12 Oct 2015 12:00pm EDT 

Stentys SA:Says sirolimus-eluting stent confirms best-in-class performance at 3 years.Clinical study confirms long-term performance of sirolimus-eluting self-Apposing stent.  Full Article

Stentys SA Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease
Monday, 28 Sep 2015 12:07pm EDT 

Stentys SA:Says that the Company's Drug-Eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries, making STENTYS' product first self-expanding and drug-eluting stent with regulatory approval in Europe for this indication.CE Mark was obtained following strong results achieved by STENTYS' stent in PES BTK-70 study in which the product prevented foot amputation in 99% of 70 patients treated for critical limb ischemia (CLI).  Full Article

More From Around the Web

BRIEF-Stentys 2016 annual revenues up 20 pct at 7.3 million euros

* 2016 annual revenues up 20 pct at 7.3 million euros ($7.78 million)